SCHEMBL30865114

SCHEMBL30865114

Cn1c(CN2CC3(C2)CN(C(=O)N2CC4(CC(n5cnc(C(F)(F)F)n5)C4)C2)C3)nnc1C(F)(F)F

nearest known ligand 0.41

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ MGLL Q99685 6/20 0.41
▸ BTK Q06187 1/20 0.30
▸ MEN1 O00255 1/20 0.30
▸ TSHR P16473 1/20 0.30
▸ KMT2A Q03164 1/20 0.30
▸ NPSR1 Q6W5P4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30865244 0.89 MGLL (0.54) MGLLMEN1TSHRKMT2ANPSR1
SCHEMBL30865169 0.81 MGLL (0.40) MGLL
SCHEMBL30865418 0.81 MGLL (0.40) MGLL
SCHEMBL30865319 0.81 MGLL (0.41) MGLL
SCHEMBL30865158 0.81 MGLL (0.47) MGLL
SCHEMBL30865482 0.80 MGLL (0.43) MGLL
SCHEMBL30865153 0.80 MGLL (0.51) MGLL
SCHEMBL30865180 0.80 MGLL (0.42) MGLL
SCHEMBL30865431 0.80 MGLL (0.46) MGLL
SCHEMBL30865281 0.80 MGLL (0.44) MGLLBTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4608823-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) F. Hoffmann-La Roche AG (CH) 2025-09-03 — — EP claimed
WO-2024088922-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) F. HOFFMANN-LA ROCHE AG (CH) 2024-05-02 — — WO claimed
EP-4608823-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) F. Hoffmann-La Roche AG (CH) 2025-09-03 — — EP disclosed
WO-2024088922-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) F. HOFFMANN-LA ROCHE AG (CH) 2024-05-02 — — WO disclosed
Send feedback